GH ResearchGHRS
About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
Employees: 49
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more call options, than puts
Call options by funds: $29K | Put options by funds: $27K
0% more funds holding
Funds holding: 28 [Q2] → 28 (+0) [Q3]
0.38% less ownership
Funds ownership: 59.04% [Q2] → 58.66% (-0.38%) [Q3]
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
43% less capital invested
Capital invested by funds: $358M [Q2] → $204M (-$154M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Cantor Fitzgerald Charles Duncan 57% 1-year accuracy 46 / 81 met price target | 2%downside $14 | Overweight Initiated | 13 Feb 2025 |
HC Wainwright & Co. Patrick Trucchio 40% 1-year accuracy 70 / 173 met price target | 180%upside $40 | Buy Reiterated | 27 Jan 2025 |
Canaccord Genuity Sumant Kulkarni 26% 1-year accuracy 9 / 34 met price target | 96%upside $28 | Buy Maintained | 18 Nov 2024 |
Financial journalist opinion
Based on 6 articles about GHRS published over the past 30 days









